Oxymorphone Hydrochloride Tablet, Film Coated, Extended Release
FDA Label NDC 0115-1316

54 label sections · Submitted to the FDA by Amneal Pharmaceuticals Of New York Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Of New York Llc for the product Oxymorphone Hydrochloride (NDC 0115-1316). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: serious and life-threatening risks from use of oxymorphone hydrochloride extended-release tablets, 1 indications and usage, 2.1 important dosage and administration instructions, 2.2  patient access to naloxone for the emergency treatment of opioid overdose, 2.4 titration and maintenance of therapy, 2.5 safe reduction or discontinuation of oxymorphone hydrochloride extended-release tablets, 2.6 dosage modification in patients with hepatic impairment, 2.7 dosage modification in patients with renal impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.